Navigation Links
Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Date:11/7/2007

Company-Sponsored "Technology Topics" Workshop Scheduled for 1 to 2 pm

Wednesday, Hyatt Regency Century Plaza, Constellation Room A.

WELLESLEY, Mass., Nov. 7 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that the company will launch its Ziplex Automated Gene-Expression System for research use only at the Association for Molecular Pathology (AMP) Annual Meeting and Exhibit, which opens today at the Hyatt Regency Century Plaza Hotel in Los Angeles. The first integrated system designed for automated gene-expression analysis, the Ziplex System comprises an automated workstation, TipChip consumable arrays, and reagents.

Xceed designed the Ziplex System to make routine molecular diagnostics both feasible and affordable. "The routine clinical laboratory will require a system that is reliable and easy to operate," said Xceed's President and CEO, David Deems. "As a fully automated and integrated platform, the Ziplex System is unmatched for both its ease-of-use and reliability of results, delivering superior accuracy, reproducibility, speed, and scalability at significantly lower cost than conventional array- or PCR-based systems. The Ziplex System allows researchers to perform testing at approximately one-third the cost and in one-third the time of conventional platforms. After the sample preparation has been completed, the hands-on time to process eight samples is approximately 20 minutes. We believe our System will help make the promise of personalized medicine a reality."

While today is the official launch of the Ziplex System, biomedical researchers across the country are already familiar with the system's performance, according to Deems. The company has been offering Expression Services for the last year, and has presented data at a number of important conferences. Deems continued, "Xceed is developing a pipeline of diagnostic assays for use on th
'/>"/>

SOURCE Xceed Molecular
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. AdvaMed 2007 Exceeds Attendance Expectations With More Than 1,100 Participants from 35 States and 25 Countries
2. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
3. A new molecular zip code, and a new drug target for Huntingtons disease
4. New knock-out gene model provides molecular clues to breast cancer
5. Molecular probe paints cancer cells in living animals, Stanford researchers find
6. Story ideas from molecular & cellular proteomics
7. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
10. Molecular profiling can accurately predict survival in colon cancer patients
11. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...n (a) levels boost cardiovascular disease risk fo...y News) -- If you,re worried about reducing your r...at you should quit smoking, eat a healthful diet, ...eck, and make sure your cholesterol levels aren,t ...ein (a) levels are? , Well, if you don,t have ...
(Date:10/10/2008)...mpany committed to helping people address health n.../ -- In these troubling,economic times, people may... may feel that they don,t have the money to visit ...a survey by the National Association of,Insurance ... -- Twenty-two percent of Americans say that they ...
(Date:10/10/2008)...Oct. 10 /PRNewswire/ -- Do you think that the blin...d town? Attend the October,17 open house at the Vi...ion Impaired, and see how instructors there empowe...ve, fulfilling lives through non-visual,techniques...1 Azalea Avenue, is holding an open house to,celeb...
(Date:10/10/2008)...omy serving as tipping point for behavior change, ...-- More than half of,Americans (51 percent) believ...are system, but major changes are needed, accordin...urvey was released today by the,Employee Benefit R...tes,Inc., and was underwritten by the Principal Fi...
Breaking Medicine News(10 mins):Health News:Little-Known Fat Can Be a Heartbreaker 2Health News:Little-Known Fat Can Be a Heartbreaker 3Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3
...were able to detect non progressive breast cancer ...ous studies// show that 54% of the mammograms dete...e is about 1% only. But the present study is based...a Zackrisson, a radiologist from the Epidemiologic...
...t satisfied with the relative success of the parti...eons are hungry to perform the // first full face ...c and Reconstructive Surgery? (PRS), the official ...c Surgeons (ASPS), U.S. plastic surgeons demonstra...
... of the Medical College of Wisconsin in Milwaukee ...MI) and those with the lowest BMI are at greatest ... slim increases male drivers risk of dying in a ca...ng moderately overweight might help cushion the bl...
...l Association journal is showing no signs of resol...ellow Sally Murray followed // Dr. John Hoey and A...ter a dispute over an article on the contraceptive...een asked to act as an interim editor, but the for...
Other Medicine News:Health News:Mammograms Detect Non Progressive Cancer 2
(Date:10/9/2008)... Company Prepares for Increased Sales and Marke...Progress of MitraClip(R) System, MENLO PARK, Cali...r in,the development of devices for the percutaneo...s and marketing executive team with the appointmen...wide sales and marketing and,Chris Richardson, as ...
(Date:10/8/2008)... ALEXANDRIA, Va., Oct. 8 /PRNewswire-USNewswi...ly 7,000 people die from HIV/AIDS in,sub-Saharan A...en in,sub-Saharan Africa have already died of AIDS...a is working to ensure the dying and their familie... end of life. FHSSA,s,innovative partnering initia...
(Date:10/8/2008)... Review Zanolimumab Program to be Discontinued a...ces the Results of its Portfolio Review; Zanolimum...l Reduce the Number of ...irstCall/ -- Genmab A/S (OMX: GEN),announced today...ab,(HuMax-CD4(R)). In addition, as a result of a p...
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical I...xpanded clinical data and new nonclinical data,dem...t may be broadly,applicable in DNA- and protein-ba...cancer vaccines. Alain P. Rolland, Pharm.D., Ph.D....ment, will present the data today,Wednesday, Octo...
Breaking Medicine Technology:Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Natural Remedies to Treat Animals Complex Emotions 23183 1Natural Remedies to Treat Animals Complex Emotions 23183 2New Ear Tube Device Helps Treat Infections Faster 23179 1New Ear Tube Device Helps Treat Infections Faster 23179 2Manhattan Scientifics Acquires Metallicum Inc 23176 1Manhattan Scientifics Acquires Metallicum Inc 23176 2Manhattan Scientifics Acquires Metallicum Inc 23176 3Manhattan Scientifics Acquires Metallicum Inc 23176 4Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 1Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 3
...ON, July 09, 2007 /PRNewswire-FirstCall/ - YM,BioS..., develops,and commercializes differentiated produ... study presented by investigators from Kinki,Unive...he 11th,meeting of The Japanese Association for Mo... 2007 demonstrated the increased,radiosensitivity ...
..., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM), a ,bio...and approval,of drugs for the treatment of metabo...nced that it will present at this,week,s C.E. Unt...s Conference in New York City. , The conference...,York City, will run from Tuesday, July 10th thro...
Other Medicine Technology:YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 2YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 3YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 4Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
Lamellar Blade tip 6600 style, angled bevel up. Dimensions: 11.0 mm (L) x 2.4 mm (W). Cut: 3.7 mm.
19 g MVR knife. Dimensions: 31.8 mm x 1.45 mm x 3.3 mm.
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.2 mm x 4.0 mm.
Full Handle Laseredge Slit Blade Knife, 3.0 mm straight. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm.
Medicine Products: